New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Bookmark and Share
Published: 30 May 2015
Views: 2364
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

Prof Chanan-Khan presents, at a press conference at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.

Read the news article and watch the interview for more.